Neo-adjuvant Chemotherapy Evluation in Gastric Cancer Patients Based on Circulating Exosomal LncRNA-GC1

Last updated: December 12, 2022
Sponsor: Chinese PLA General Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Stomach Cancer

Gastric Cancer

Digestive System Neoplasms

Treatment

N/A

Clinical Study ID

NCT05647941
neo-Biomarker
  • Ages 18-80
  • All Genders

Study Summary

The investigators hope that through the analysis and research to find determine whether lncRNA-GC1 could serve as a non-invasive biomarker for monitoring the neo-adjuvant chemotherapy response for personalized medicine for gastric cancer.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Having signed informed consent
  • Age≥ 18 years old
  • Histologically confirmed gastric adenocarcinoma
  • radiographically identified as advanced gastric cancer

Exclusion

Exclusion Criteria:

  • Other previous malignancy within 5 year
  • Surgery (excluding diagnostic biopsy) within 4 weeks prior to study
  • Pregnancy or lactation period
  • Legal incapacity

Study Design

Total Participants: 700
Study Start date:
January 01, 2018
Estimated Completion Date:
December 30, 2022

Study Description

The LncRNA-GC1could noninvasively track dynamics of tumor burden and has been proposed as a real-time biomarker that can provide both predictive and prognostic values. But the value in monitoring the neo-adjuvant chemotherapy response is unclear. The investigators hope that through the analysis and research to find determine whether lncRNA-GC1 could serve as a monitoring biomarker for patients with gastric cancer receiving neo-adjuvant chemotherapy.

Connect with a study center

  • Chinese PLA General Hospital Ethics Committee

    Beijing, Beijing 100853
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.